BackgroundCheck.run
Search For

Yong Mei Zhang, 53Pomona, CA

Known as:
Yong M Zhang Yongmei Zhang
Related to:
Shu J Zhang 49 Xiu Yun Zhang 50

Yong Zhang Phones & Addresses

Pomona, CA   

La Puente, CA   

West Memphis, AR   

Marion, AR   

New York, NY   

La Puente, CA   

Get Report
Control this profile

Mentions for Yong Mei Zhang

Career records & work history

Medicine Doctors

Yong Zhang

Specialties:
Internal Medicine
Work:
Kaiser Permanente Medical GroupKaiser Walnut Creek Medical Group
1425 S Main St, Walnut Creek, CA 94596
925-2954000 (phone)
Site
Education:
Medical School
Kath Univ Leuven, Fac Der Geneeskunde, Leuven, Belgium
Graduated: 1987
Procedures:
Destruction of Benign/Premalignant Skin Lesions, Vaccine Administration
Conditions:
Abdominal Hernia, Acne, Acute Pharyngitis, Alopecia Areata, Anxiety Phobic Disorders, Benign Paroxysmal Positional Vertigo, Bronchial Asthma, Carpel Tunnel Syndrome, Contact Dermatitis, Dermatitis, Diabetes Mellitus (DM), Disorders of Lipoid Metabolism, Eating Disorders, Fractures, Dislocations, Derangement, and Sprains, Gastroesophageal Reflux Disease (GERD), Hallux Valgus, Heart Failure, Hemorrhoids, Herpes Genitalis, Herpes Simplex, Hypertension (HTN), Hypothyroidism, Intervertebral Disc Degeneration, Lateral Epicondylitis, Migraine Headache, Otitis Media, Plantar Fascitis, Rotator Cuff Syndrome and Allied Disorders, Scoliosis or Kyphoscoliosis, Skin and Subcutaneous Infections, Substance Abuse and/or Dependency, Varicose Veins
Languages:
English, Spanish, Vietnamese
Description:
Dr. Zhang graduated from the Kath Univ Leuven, Fac Der Geneeskunde, Leuven, Belgium in 1987. She works in Walnut Creek, CA and specializes in Internal Medicine. Dr. Zhang is affiliated with Kaiser Permanente Walnut Creek Medical Center.

License Records

Yong Wei Zhang

Licenses:
License #: 2710053787
Category: Tradesman

Yong Zhang resumes & CV records

Resumes

Yong Zhang Photo 37

Research Associate At The Scripps Research Institute

Position:
Research Associate at The Scripps Research Institute
Location:
San Diego, California
Industry:
Pharmaceuticals
Work:
The Scripps Research Institute - Greater San Diego Area since Jul 2011
Research Associate University of Guelph Mar 2004 - May 2006
Graduate Student
Education:
Albert Einstein College of Medicine of Yeshiva University 2006 - 2011
Ph.D., Biochemistry University of Guelph 2004 - 2006
M.Sc., Biophysics Shandong University 1999 - 2003
B.Sc., Biological Sciences
Yong Zhang Photo 38

Senior Director, Embedded Software Engineering At Fortinet

Position:
Senior Director, Embedded Software Engineering at Fortinet
Location:
Sunnyvale, California
Industry:
Computer Networking
Work:
Fortinet - Sunnyvale, CA since Apr 2008
Senior Director, Embedded Software Engineering LGC Wireless (acquired by ADC telecommunications) Apr 2007 - Apr 2008
Senior Software Engineer Strix Systems Aug 2006 - Apr 2007
Senior Software Engineer Novatel Wireless Nov 2005 - Aug 2006
Senior Software Engineer Solectek May 2005 - Nov 2005
Senior Software Engineer Marconi (acquired by Ericsson) Jan 2001 - Apr 2005
Software engineer
Education:
Drexel University 1998 - 2000
MS, Electrical and Electronics Engineering Institute of Electronics, Chinese Academy of Sciences 1995 - 1998
MS, Electrical and Electronics Engineering Tsinghua University 1990 - 1995
BS, Engineering Physics
Skills:
Embedded Systems, Wireless, WiFi, TCP/IP, Linux, Device Drivers, Linux Kernel, C, Perl, IP, VoIP, C++
Yong Zhang Photo 39

Yong Zhang

Location:
United States
Yong Zhang Photo 40

Yong Min Zhang - California

Work:
restaurant - ca Mar 2011 to Sep 2012
sushi chef
Education:
shen yang college - shen yang 2007 to 2009
college cook in cook

Publications & IP owners

Us Patents

Compounds For The Treatment Of Dyslipidemia And Other Lipid Disorders

US Patent:
7629372, Dec 8, 2009
Filed:
Sep 12, 2005
Appl. No.:
11/662808
Inventors:
James F. Dropinski - Colts Neck NJ, US
Guo Q. Shi - Monmouth Junction NJ, US
Yong Zhang - West Windsor NJ, US
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 31/423
C07D 261/20
US Classification:
514379, 548240, 548241, 514378
Abstract:
A class of compounds having Formula I and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of developing conditions and sequelae that are associated with these diseases, such as atherosclerosis.

Antidiabetic Oxazolidinediones And Thiazolidinediones

US Patent:
7807692, Oct 5, 2010
Filed:
Jun 30, 2006
Appl. No.:
11/922628
Inventors:
James F. Dropinski - Colts Neck NJ, US
Peter T. Meinke - Scotch Plains NJ, US
Guo Q. Shi - Monmouth Junction NJ, US
Yong Zhang - West Windsor NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/47
A61K 31/42
A61K 31/44
C07D 413/00
C07D 215/02
C07D 263/00
US Classification:
514307, 514314, 514376, 514340, 5462714, 546166, 548227
Abstract:
Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

Fused-Aromatic Compounds Having Anti-Diabetic Activity

US Patent:
7834036, Nov 16, 2010
Filed:
Mar 3, 2006
Appl. No.:
11/884802
Inventors:
Harold B. Wood - Westfield NJ, US
Peter T. Meinke - Scotch Plains NJ, US
Guo Q. Shi - Monmouth Junction NJ, US
Yong Zhang - West Windsor NJ, US
Assignee:
Merck Sharp & Dohme Corp - Rahway NJ
International Classification:
A61K 31/443
C07D 413/04
US Classification:
514338, 5462721
Abstract:
Fused aromatic compounds of Formula (I) are PPAR gamma agonists or partial agonists and are useful in the treatment or control of type II diabetes, including hyperglycemia, dyslipidermia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.

Substituted Cyclopropyl Compounds, Compositions Containing Such Compounds And Methods Of Treatment

US Patent:
8552022, Oct 8, 2013
Filed:
Aug 3, 2010
Appl. No.:
13/390147
Inventors:
Harold B. Wood - Westfield NJ, US
Alan D. Adams - Holland NY, US
Jason W. Szewczyk - New York NY, US
Yong Zhang - West Windsor NJ, US
Meng Yang - Westfield NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/505
C07D 239/02
C07D 403/04
US Classification:
514275, 544330, 544295, 544331
Abstract:
Substituted cyclopropyl compounds of the formula I: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

Composition Comprising Scutellaria Baicalensis And Their Uses Thereof

US Patent:
2006016, Jul 27, 2006
Filed:
Dec 26, 2003
Appl. No.:
10/540817
Inventors:
Yong Zhang - Jamaica NY, US
Fei Ye - Beijing, CN
Fan Li - Beijing, CN
International Classification:
A61K 36/539
A61K 31/737
A61K 31/7008
US Classification:
424741000, 514062000, 514054000
Abstract:
This invention described various formula composite of for various diseases and conditions. The formula takes the advantage of our recent discovery of can inhibit cyclooxygenase-2 (COX-2) activity and expression, resulting in decrease of prostaglandin synthesis. COX-2 is involved in many biological processes, such as inflammation, pain, carcinogenesis, etc. Combination of with lycopene can be used for cancer prevention, especially smoking induced. Combination of with glucosamine and chondroitin can be used for arthritis. Finally, this invention disclosed various method to prepare this formula and composition.

Rna Interferases And Methods Of Use Thereof

US Patent:
2013007, Mar 21, 2013
Filed:
Apr 17, 2012
Appl. No.:
13/449095
Inventors:
Masayori Inouye - New Brunswick NJ, US
Junjie Zhang - Edison NJ, US
Yong Long Zhang - Highland Park NJ, US
Assignee:
UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - Somerset NJ
International Classification:
C12N 9/22
C12P 19/34
A61K 38/46
C12Q 1/44
US Classification:
424 9461, 435 61, 435199, 435 912, 536 232
Abstract:
The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds/agents capable of modulating mRNA interferase activity and methods for using such compounds/agents. Also provided is a kit comprising mRNA interferase nucleic and/or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials.

Novel Prolylcarboxypeptidase Inhibitors

US Patent:
2013021, Aug 22, 2013
Filed:
May 12, 2011
Appl. No.:
13/642584
Inventors:
John S. Debenham - Scotch Plains NJ, US
Thomas H. Graham - Scotch Plains NJ, US
Matthew J. Clements - Old Bridge NJ, US
Yong Zhang - West Windsor NJ, US
International Classification:
C07C 237/24
C07D 295/155
A61K 31/165
C07D 213/40
A61K 31/5377
C07D 241/12
C07D 239/26
A61K 31/397
C07D 205/04
A61K 31/4453
A61K 31/40
C07D 233/61
A61K 31/4164
A61K 45/06
C07C 271/24
C07D 213/61
A61K 31/5375
US Classification:
51421002, 5142395, 544169, 564167, 514619, 544131, 5142355, 544120, 5142358, 544122, 564157, 514616, 564155, 51421001, 548950, 514331, 546234, 548567, 514428, 5483381, 514399, 514346, 514249, 514485, 514479, 560 27, 544163, 564168, 514460
Abstract:
Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.

Methods Of Treatment And Prevention Of Alzheimer's Disease

US Patent:
2021032, Oct 21, 2021
Filed:
Jul 23, 2019
Appl. No.:
17/250448
Inventors:
- Tokyo, JP
Chad J. SWANSON - Woodcliff Lake NJ, US
Yong ZHANG - Woodcliff Lake NJ, US
Shobha DHADDA - Woodcliff Lake NJ, US
Jinping WANG - Woodcliff Lake NJ, US
Lynn KRAMER - Woodcliff Lake NJ, US
International Classification:
C07K 16/18
A61K 31/542
A61P 25/28
Abstract:
Provided herein are methods of reducing clinical decline in a subject having early Alzheimer's disease, methods of converting an amyloid positive subject having early Alzheimer's disease to amyloid negative, methods of reducing brain amyloid level in a subject, and methods of preventing Alzheimer's disease, the methods comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject is ApoE4-positive. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.

Isbn (Books And Publications)

Fu Da Shi Yan Jiu

Author:
Yong Zhang
ISBN #:
7806590471

Changing Tax Law In East And Southeast Asia Towards The 21St Century

Author:
Yong Zhang
ISBN #:
9041104917

Comparative Studies On Governmental Liability In East And Southeast Asia

Author:
Yong Zhang
ISBN #:
9041110747

Possible Relatives

David Zhang  Dawei Zhang  Dazhi Zhang  De K Zhang  Da Q Zhang  Dachuan Zhang  Daijun Zhang  Yong I Johnson  Yong S White  Yong C Stanley 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.